 Jennifer Shannon
Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urate Oxidase | 1 | 2012 | 13 | 0.360 |
Why?
| | Gout Suppressants | 1 | 2012 | 20 | 0.360 |
Why?
| | Enzymes, Immobilized | 1 | 2012 | 30 | 0.350 |
Why?
| | Gout | 1 | 2012 | 35 | 0.350 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 655 | 0.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 1958 | 0.230 |
Why?
| | Adenocarcinoma | 3 | 2016 | 931 | 0.170 |
Why?
| | ras Proteins | 1 | 2021 | 151 | 0.160 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2021 | 226 | 0.150 |
Why?
| | Margins of Excision | 1 | 2019 | 51 | 0.140 |
Why?
| | Fluorouracil | 5 | 2021 | 235 | 0.140 |
Why?
| | Pancreatic Neoplasms | 2 | 2019 | 927 | 0.140 |
Why?
| | Colorectal Neoplasms | 2 | 2021 | 848 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 642 | 0.130 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 653 | 0.130 |
Why?
| | Deoxycytidine | 2 | 2019 | 221 | 0.120 |
Why?
| | Pancreatectomy | 1 | 2019 | 285 | 0.120 |
Why?
| | Esophagogastric Junction | 1 | 2016 | 56 | 0.120 |
Why?
| | Liver Neoplasms | 2 | 2016 | 783 | 0.110 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2019 | 292 | 0.110 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 103 | 0.110 |
Why?
| | Stomach Neoplasms | 1 | 2016 | 128 | 0.100 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2013 | 20 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 1141 | 0.100 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 105 | 0.100 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2197 | 0.090 |
Why?
| | Esophageal Neoplasms | 1 | 2016 | 349 | 0.090 |
Why?
| | Prognosis | 3 | 2021 | 4293 | 0.080 |
Why?
| | Health Expenditures | 1 | 2012 | 194 | 0.080 |
Why?
| | Heart Failure | 1 | 2024 | 2323 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 4099 | 0.080 |
Why?
| | Skin Neoplasms | 2 | 2009 | 847 | 0.080 |
Why?
| | Leucovorin | 3 | 2019 | 101 | 0.080 |
Why?
| | Disease-Free Survival | 4 | 2016 | 769 | 0.070 |
Why?
| | Lymphatic Metastasis | 4 | 2016 | 334 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2007 | 222 | 0.070 |
Why?
| | Yttrium Radioisotopes | 1 | 2007 | 64 | 0.060 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1322 | 0.060 |
Why?
| | Brachytherapy | 1 | 2007 | 134 | 0.060 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2005 | 16 | 0.060 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2004 | 7 | 0.050 |
Why?
| | Embolization, Therapeutic | 1 | 2007 | 242 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2004 | 36 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 2009 | 562 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2021 | 695 | 0.050 |
Why?
| | Benzhydryl Compounds | 1 | 2024 | 82 | 0.050 |
Why?
| | Glycine | 1 | 2024 | 187 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2019 | 421 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2642 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 77 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 405 | 0.040 |
Why?
| | Risk Assessment | 1 | 2009 | 3676 | 0.040 |
Why?
| | Treatment Outcome | 5 | 2016 | 11695 | 0.040 |
Why?
| | Aged | 6 | 2021 | 25947 | 0.040 |
Why?
| | Humans | 10 | 2024 | 144957 | 0.030 |
Why?
| | Prospective Studies | 2 | 2021 | 7997 | 0.030 |
Why?
| | Anorexia | 1 | 2016 | 17 | 0.030 |
Why?
| | Capecitabine | 1 | 2016 | 57 | 0.030 |
Why?
| | Taxoids | 1 | 2016 | 116 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1385 | 0.030 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.030 |
Why?
| | Vomiting | 1 | 2016 | 130 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1721 | 0.030 |
Why?
| | Diarrhea | 1 | 2016 | 192 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 334 | 0.030 |
Why?
| | Fatigue | 1 | 2016 | 366 | 0.020 |
Why?
| | Male | 7 | 2021 | 72406 | 0.020 |
Why?
| | Europe | 1 | 2013 | 412 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5417 | 0.020 |
Why?
| | Middle Aged | 5 | 2016 | 35928 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 966 | 0.020 |
Why?
| | Female | 6 | 2021 | 78376 | 0.020 |
Why?
| | Animals | 1 | 2012 | 38109 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 1524 | 0.020 |
Why?
| | Adult | 4 | 2016 | 40506 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2007 | 66 | 0.020 |
Why?
| | Vitamin B Complex | 1 | 2007 | 40 | 0.020 |
Why?
| | Microspheres | 1 | 2007 | 142 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2007 | 212 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2007 | 207 | 0.010 |
Why?
| | Australia | 1 | 2007 | 286 | 0.010 |
Why?
| | United Kingdom | 1 | 2007 | 338 | 0.010 |
Why?
| | Recurrence | 1 | 2009 | 1135 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 2009 | 8279 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2004 | 307 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2118 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2005 | 1268 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 1325 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1077 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 17101 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2004 | 1495 | 0.010 |
Why?
| | Survival Rate | 1 | 2005 | 2092 | 0.010 |
Why?
| | Time Factors | 1 | 2007 | 7183 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2004 | 2738 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2004 | 3869 | 0.010 |
Why?
|
|
Shannon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|